Keyword: Aurobindo Pharma
The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.
Litigation is growing over tainted blood pressure medications with a class-action lawsuit now filed in Florida against Walmart and three drug companies that span the supply chain.
Ex-Roche scientists were charged with stealing trade secrets; Astellas invested in gene and cell therapy; Takeda touted growth in key focus areas.
The FDA says a probable cancer-causing ingredient has been found in yet another blood pressure treatment in the U.S.
China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.
Investors might see the deal as "a proxy for what the commodity portions of Teva’s U.S. and Mylan’s U.S. businesses might be worth," says an analyst.
Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.
The deal relieves Novartis of a troubled franchise while boosting buyer Aurobindo to the second-largest generics player by prescriptions in the U.S.
Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.
India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.